NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its third-quarter 2012 revenues jumped 27 percent.

The Salt Lake City-based molecular diagnostics firm reported total revenues of $129.8 million for the three-month period ended March 31, up from $102.4 million for Q3 2011. It easily beat Wall Street's consensus estimate for revenues of $119.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.